[Federal Register Volume 78, Number 221 (Friday, November 15, 2013)]
[Rules and Regulations]
[Pages 68716-68719]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-27315]
[[Page 68716]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA-382]
Schedules of Controlled Substances: Temporary Placement of Three
Synthetic Phenethylamines Into Schedule I
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Final order.
-----------------------------------------------------------------------
SUMMARY: The Deputy Administrator of the Drug Enforcement
Administration (DEA) is issuing this final order to temporarily
schedule three synthetic phenethylamines into the Controlled Substances
Act (CSA) pursuant to the temporary scheduling provisions of 21 U.S.C.
811(h). The substances are 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5), 2-(4-
chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe;
2C-C-NBOMe; 25C; Cimbi-82), and 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)
[hereinafter 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe]. This action is based
on a finding by the Deputy Administrator that the placement of these
synthetic phenethylamines and their optical, positional, and geometric
isomers, salts and salts of isomers in schedule I of the CSA is
necessary to avoid an imminent hazard to the public safety. As a result
of this order, the regulatory controls and administrative, civil, and
criminal sanctions applicable to schedule I controlled substances will
be imposed on persons who handle (manufacture, distribute, dispense,
import, export, engage in research, conduct instructional activities,
and possess), or propose to handle these synthetic phenethylamines.
DATES: This final order is effective November 15, 2013.
FOR FURTHER INFORMATION CONTACT: Ruth A. Carter, Chief, Policy
Evaluation and Analysis Section, Office of Diversion Control, Drug
Enforcement Administration; Mailing Address: 8701 Morrissette Drive,
Springfield, Virginia 22152, Telephone (202) 598-6812.
SUPPLEMENTARY INFORMATION:
Legal Authority
The DEA implements and enforces titles II and III of the
Comprehensive Drug Abuse Prevention and Control Act of 1970, as
amended. Titles II and III are referred to as the ``Controlled
Substances Act'' and the ``Controlled Substances Import and Export
Act,'' respectively, but they are collectively referred to as the
``Controlled Substances Act'' or the ``CSA'' for the purpose of this
action. 21 U.S.C. 801-971. The DEA publishes the implementing
regulations for these statutes in title 21 of the Code of Federal
Regulations (CFR), parts 1300 to 1321. The CSA and its implementing
regulations are designed to prevent, detect, and eliminate the
diversion of controlled substances and listed chemicals into the
illicit market while providing for legitimate medical, scientific,
research, and industrial needs of the United States. Controlled
substances have the potential for abuse and dependence and are
controlled to protect the public health and safety.
Under the CSA, controlled substances are classified into one of
five schedules based upon their potential for abuse, their currently
accepted medical use, and the degree of dependence the substance may
cause. 21 U.S.C. 812. The initial schedules of controlled substances
established by Congress are found at 21 U.S.C. 812(c), and the current
list of all scheduled substances is published at 21 CFR part 1308.
Section 201 of the CSA, 21 U.S.C. 811, provides the Attorney
General with the authority to temporarily place a substance into
schedule I of the CSA for two years, without regard to the requirements
of 21 U.S.C. 811(b), if he finds that such action is necessary to avoid
an imminent hazard to the public safety. 21 U.S.C. 811(h). In addition,
if proceedings to control a substance are initiated under 21 U.S.C.
811(a)(1), the Attorney General may extend the temporary scheduling for
up to one year. 21 U.S.C. 811(h)(2).
Where the necessary findings are made, a substance may be
temporarily scheduled if it is not listed in any other schedule under
section 202 of the CSA, 21 U.S.C. 812, or if there is no exemption or
approval in effect under section 505 of the Federal Food, Drug, and
Cosmetic Act (FD&C Act), 21 U.S.C. 355, for the substance. 21 U.S.C.
811(h)(1). Pursuant to 21 U.S.C. 871(a), the Attorney General has
delegated his scheduling authority under 21 U.S.C. 811 to the
Administrator of the DEA, who in turn has delegated her authority to
the Deputy Administrator of the DEA. 28 CFR 0.100, 0.104.
Background
Section 201(h)(4) of the CSA, 21 U.S.C. 811(h)(4), requires the
Deputy Administrator to notify the Secretary of the Department of
Health and Human Services (HHS) of his intention to temporarily place a
substance in schedule I of the CSA.\1\ The Deputy Administrator
transmitted notice of his intent to place 25I-NBOMe, 25C-NBOMe, and
25B-NBOMe in schedule I on a temporary basis to the Assistant Secretary
by letter dated September 3, 2013. The Assistant Secretary responded to
this notice by letter dated October 1, 2013 (received by the DEA on
October 8, 2013), and advised that based on review by the FDA, there
are currently no investigational new drug applications or approved new
drug applications for 25I-NBOMe, 25C-NBOMe, or 25B-NBOMe. The Assistant
Secretary also stated that the HHS has no objection to the temporary
placement of 25I-NBOMe, 25C-NBOMe, or 25B-NBOMe in schedule I of the
CSA. The DEA has taken into consideration the Assistant Secretary's
comments as required by 21 U.S.C. 811(h)(4). As 25I-NBOMe, 25C-NBOMe,
and 25B-NBOMe are not currently listed in any schedule under the CSA,
and as no exemptions or approvals are in effect for 25I-NBOMe, 25C-
NBOMe, and 25B-NBOMe under section 505 of the FD&C Act, 21 U.S.C. 355,
the conditions of 21 U.S.C. 811(h)(1) have been satisfied. As required
by 21 U.S.C. 811(h)(1)(a), a notice of intent to temporarily schedule
these three synthetic phenethylamines was published in the Federal
Register on October 10, 2013. 78 FR 61991.
---------------------------------------------------------------------------
\1\ Because the Secretary of the HHS has delegated to the
Assistant Secretary for Health of the HHS the authority to make
domestic drug scheduling recommendations, for purposes of this Final
Order, all subsequent references to ``Secretary'' have been replaced
with ``Assistant Secretary.'' As set forth in a memorandum of
understanding entered into by the HHS, the Food and Drug
Administration (FDA), and the National Institute on Drug Abuse
(NIDA), the FDA acts as the lead agency within the HHS in carrying
out the Assistant Secretary's scheduling responsibilities under the
CSA, with the concurrence of the NIDA. 50 FR 9518, Mar. 8, 1985.
---------------------------------------------------------------------------
To make a finding that placing a substance temporarily in schedule
I of the CSA is necessary to avoid an imminent hazard to the public
safety, the Deputy Administrator is required to consider three of the
eight factors set forth in section 201(c) of the CSA, 21 U.S.C. 811(c):
The substance's history and current pattern of abuse; the scope,
duration, and significance of abuse; and what, if any, risk there is to
the public health. 21 U.S.C. 811(c)(4)-(6). Consideration of these
factors includes actual abuse, diversion from legitimate channels, and
clandestine importation, manufacture, or distribution. 21 U.S.C.
811(h)(3).
A substance meeting the statutory requirements for temporary
scheduling may only be placed in schedule I. 21
[[Page 68717]]
U.S.C. 811(h)(1). Substances in schedule I are those that have a high
potential for abuse, no currently accepted medical use in treatment in
the United States, and a lack of accepted safety for use under medical
supervision. 21 U.S.C. 812(b)(1). Available data and information for
25I-NBOMe, 25C-NBOMe, and 25B-NBOMe indicate that these three synthetic
phenethylamines have a high potential for abuse, no currently accepted
medical use in treatment in the United States, and a lack of accepted
safety for use under medical supervision.
Synthetic Phenethylamines
The 2-methoxybenzyl series of 2C phenethylamine substances, such as
25I-NBOMe, 25C-NBOMe, and 25B-NBOMe, has been developed over the last
10 years for use in mapping and investigating the serotonin receptors
in the mammalian brain. 25I-NBOMe and 25B-NBOMe were first described by
legitimate research laboratories in 2003. Subsequent studies involving
these two substances appeared in the scientific literature starting in
2006. 25C-NBOMe first appeared in the scientific literature in 2011. No
approved medical use has been identified for these synthetic
phenethylamines, nor have they been approved by the FDA for human
consumption. Synthetic 2C phenethylamine substances, of which 25I-
NBOMe, 25C-NBOMe, and 25B-NBOMe are representative, are so-termed for
the two-carbon ethylene group between the phenyl ring and the amino
group of the phenethylamine and are substituted with methoxy groups at
the 2 and 5 positions of the phenyl ring. Numerous blotter papers and
food items have been analyzed, and combinations of one or more of 25I-
NBOMe, 25C-NBOMe, and 25B-NBOMe have been identified as adulterants.
Bulk quantities of these substances have been encountered as powders
and liquid solutions.
From November 2011 through June 2013, according to the System to
Retrieve Information from Drug Evidence \2\ (STRIDE) data, there are 54
exhibits involving 27 cases for 25I-NBOMe; 27 exhibits involving 12
cases for 25C-NBOMe; and 4 exhibits involving 4 cases for 25B-NBOMe.
From June 2011 through June 2013, the National Forensic Laboratory
Information System \3\ (NFLIS) registered 959 reports containing these
synthetic phenethylamines (25I-NBOMe--795 reports; 25C-NBOMe--144
reports; 25B-NBOMe--20 reports) across 35 States. No instances
involving 25I-NBOMe, 25C-NBOMe, or 25B-NBOMe were reported in NFLIS
prior to June 2011.
---------------------------------------------------------------------------
\2\ STRIDE includes data on analyzed samples from DEA
laboratories.
\3\ NFLIS is a database that collects scientifically verified
data on analyzed samples in State and local forensic laboratories.
---------------------------------------------------------------------------
Factor 4. History and Current Pattern of Abuse
One or more 2-methoxybenzyl analogues of the 2C compounds described
here have been available over the Internet since 2010. The first
identified domestic law enforcement encounter with 25I-NBOMe occurred
in June 2011 in Milwaukee, Wisconsin.
Information from published studies and law enforcement reports,
supplemented with discussions on Internet Web sites and personal
communications, document abuse of 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe
by nasal insufflation of powders, intravenous injection or nasal
absorption of liquid solutions, sublingual or buccal administration of
blotter papers, and consumption of food items laced with these
substances. These sources also report that 25I-NBOMe, 25C-NBOMe, and
25B-NBOMe are often purported to be schedule I hallucinogens like
lysergic acid diethylamide (LSD). Reports document that the abuse of
these substances can cause severe toxic reactions, including death.
According to United States Customs and Border Protection data, bulk
quantities of powdered 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe have been
seized from shipments originating overseas, particularly from Asia.
Given the relatively small quantity of these substances predicted to
produce a hallucinogenic effect in humans, single seizures of these
substances are capable of producing hundreds of thousands to millions
of dosage units. Large seizures of these substances prepared on blotter
papers have also been reported. Abuse of 25I-NBOMe, 25C-NBOMe, and 25B-
NBOMe has been characterized with acute public health and safety issues
domestically and abroad. In response, a number of States and foreign
governments have controlled these substances.
Factor 5. Scope, Duration, and Significance of Abuse
According to forensic laboratory reports, the first law enforcement
encounter with 25I-NBOMe in the United States occurred in June 2011.
According to NFLIS, 959 exhibits involving 25I-NBOMe, 25C-NBOMe, and
25B-NBOMe were submitted to forensic laboratories between June 2011 and
June 2013 from a number of States including Alabama, Arizona, Arkansas,
California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana,
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Michigan,
Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New
Mexico, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina,
Tennessee, Texas, Utah, Virginia, Wisconsin, and Wyoming. The number of
reports submitted to NFLIS involving 25I-NBOMe, 25C-NBOMe, and 25B-
NBOMe has increased in each of the last five quarters where complete
data is available. According to STRIDE, there are 85 records that
identify 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe in evidence submitted to
DEA laboratories between November 2011 and June 2013.
Factor 6. What, If Any, Risk There Is to the Public Health
In 2012 and 2013, emergency department physicians and toxicologists
published and presented numerous case reports of patients treated for
exposure to 25I-NBOMe. The adverse health effects reported include
tachycardia, hypertension, agitation, aggression, visual and auditory
hallucinations, seizures, hyperpyrexia, clonus, elevated white cell
count, elevated creatine kinase, metabolic acidosis, rhabdomyolysis,
and acute kidney injury.
Medical examiner and postmortem toxicology reports from 11 States
implicate some combination of 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe in
the death of at least 17 individuals. These reports suggest that 14
individuals died of acute toxicity, and 3 individuals died of
unpredictable or violent behavior due to 25I-NBOMe toxicity. 25I-NBOMe,
25C-NBOMe, and 25B-NBOMe have each been detected in postmortem blood
toxicology for cases of acute toxicity.
Since abusers obtain these drugs through unknown sources, the
identity, purity, and quantity of these substances is uncertain and
inconsistent, thus posing significant adverse health risks to users.
There are no recognized therapeutic uses for these substances in the
United States and possible deadly drug interactions between 25I-NBOMe
and FDA-approved medications have been noted.
Finding of Necessity of Schedule I Placement To Avoid Imminent Hazard
to Public Safety
Based on the above data and information, the continued uncontrolled
manufacture, distribution, importation, exportation, and abuse of 25I-
NBOMe, 25C-NBOMe, and 25B-NBOMe pose an
[[Page 68718]]
imminent hazard to the public safety. The DEA is not aware of any
currently accepted medical uses for these synthetic phenethylamines in
the United States. A substance meeting the statutory requirements for
temporary scheduling, 21 U.S.C. 811(h)(1), may only be placed in
schedule I. Substances in schedule I are those that have a high
potential for abuse, no currently accepted medical use in treatment in
the United States, and a lack of accepted safety for use under medical
supervision. Available data and information for 25I-NBOMe, 25C-NBOMe,
and 25B-NBOMe indicate that these three synthetic phenethylamines have
a high potential for abuse, no currently accepted medical use in
treatment in the United States, and a lack of accepted safety for use
under medical supervision. As required by section 201(h)(4) of the CSA,
21 U.S.C. 811(h)(4), the Deputy Administrator through a letter dated
September 3, 2013, notified the Assistant Secretary of the intention to
temporarily place these three synthetic phenethylamines in schedule I.
Conclusion
In accordance with the provisions of section 201(h) of the CSA, 21
U.S.C. 811(h), the Deputy Administrator considered available data and
information, herein set forth the grounds for his determination that it
is necessary to temporarily schedule three synthetic phenethylamines,
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-
NBOMe; 2C-I-NBOMe; 25I; Cimbi-5), 2-(4-chloro-2,5-dimethoxyphenyl)-N-
(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) and
2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-
NBOMe; 2C-B-NBOMe; 25B; Cimbi-36), in schedule I of the CSA, and finds
that placement of these synthetic phenethylamines in schedule I of the
CSA is necessary to avoid an imminent hazard to the public safety.
Because the Deputy Administrator hereby finds it necessary to
temporarily place these synthetic phenethylamines in schedule I to
avoid an imminent hazard to the public safety, the final order
temporarily scheduling these substances will be effective on the date
of publication in the Federal Register, and will be in effect for a
period of two years, with a possible extension of one additional year,
pending completion of the permanent or regular scheduling process. 21
U.S.C. 811(h)(1)-(2).
The CSA sets forth specific criteria for scheduling a drug or other
substance. Regular scheduling actions in accordance with 21 U.S.C.
811(a) are subject to formal rulemaking procedures done ``on the record
after opportunity for a hearing'' conducted pursuant to the provisions
of 5 U.S.C. 556 and 557. 21 U.S.C. 811. The regular scheduling process
of formal rulemaking affords interested parties with appropriate
process and the government with any additional relevant information
needed to make a determination. Final decisions that conclude the
regular scheduling process of formal rulemaking are subject to judicial
review. 21 U.S.C. 877. Temporary scheduling orders are not subject to
judicial review. 21 U.S.C. 811(h)(6).
Regulatory Requirements
Upon the effective date of this Final Order, 25I-NBOMe, 25C-NBOMe,
and 25B-NBOMe will become subject to the CSA's schedule I regulatory
controls and administrative, civil, and criminal sanctions applicable
to the manufacture, distribution, importation, exportation, research,
conduct of instructional activities, and possession including the
following:
1. Registration. Any person who handles (manufactures, distributes,
dispenses, imports, exports, engages in research, conducts
instructional activities, or possesses), or desires to handle, 25I-
NBOMe, 25C-NBOMe, or 25B-NBOMe must be registered with the DEA to
conduct such activities pursuant to 21 U.S.C. 822, 823, 957, and 958,
and in accordance with 21 CFR parts 1301 and 1312. Any person who
currently handles 25I-NBOMe, 25C-NBOMe, or 25B-NBOMe, and is not
registered with the DEA must submit an application for registration and
may not continue his/her activities until the DEA has approved that
application. Retail sales of schedule I controlled substances to the
general public are not allowed under the CSA.
2. Security. 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe are subject to
schedule I security requirements and must be handled and stored in
accordance with 21 CFR 1301.71-1301.93, pursuant to 21 U.S.C. 821, 823,
871(b), as of November 15, 2013.
3. Labeling and packaging. All labeling and packaging requirements
for controlled substances set forth in part 1302 of title 21 of the CFR
shall apply to commercial containers of 25I-NBOMe, 25C-NBOMe, and 25B-
NBOMe. Current DEA registrants shall have 30 calendar days from
November 15, 2013 to comply with all labeling and packaging
requirements.
4. Quotas. Quotas for 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe will be
established based on registrations granted and quota applications
received pursuant to part 1303 of title 21 of the CFR.
5. Inventory. Every DEA registrant who possesses any quantity of
25I-NBOMe, 25C-NBOMe, or 25B-NBOMe on the effective date of this order
will be required to take an inventory of all stocks of these substances
on hand as of the effective date of this order, pursuant to 21 U.S.C.
827, 958(e), and in accordance with 21 CFR 1304.03, 1304.04, and
1304.11. Current DEA registrants shall have 30 calendar days from the
effective date of this order to be in compliance with all inventory
requirements.
6. Records. All registrants who are authorized to handle 25I-NBOMe,
25C-NBOMe, or 25B-NBOMe are required to keep records pursuant to
1304.03, 1304.04, 1304.21, 1304.22, and 1304.23 of title 21 of the CFR.
Current DEA registrants authorized to handle 25I-NBOMe, 25C-NBOMe, or
25B-NBOMe shall have 30 calendar days from the effective date of this
order to be in compliance with all recordkeeping requirements.
7. Reports. All registrants are required to submit reports in
accordance with 1304.33 of title 21 of the CFR. DEA registrants who
manufacture or distribute 25I-NBOMe, 25C-NBOMe, or 25B-NBOMe are
required to comply with these reporting requirements and shall do so as
of November 15, 2013.
8. Order Forms. All registrants involved in the distribution of
25I-NBOMe, 25C-NBOMe, or 25B-NBOMe must comply with order form
requirements of part 1305 of title 21 of the CFR as of November 15,
2013.
9. Importation and Exportation. All importation and exportation of
25I-NBOMe, 25C-NBOMe, or 25B-NBOMe must be conducted by appropriately
registered DEA registrants in compliance with part 1312 of title 21 of
the CFR, pursuant to 21 U.S.C. 952, 953, 957, and 958, on or after
November 15, 2013.
10. Criminal Liability. Any activity involving 25I-NBOMe, 25C-
NBOMe, or 25B-NBOMe not authorized by, or in violation of the CSA,
occurring as of November 15, 2013 is unlawful, and may subject the
person to administrative, civil, and criminal proceedings.
Regulatory Matters
Section 201(h) of the CSA, 21 U.S.C. 811(h), provides for an
expedited temporary scheduling action where such action is necessary to
avoid an imminent hazard to the public safety. As provided in this
subsection, the Attorney General may, by order,
[[Page 68719]]
schedule a substance in schedule I on a temporary basis. Such an order
may not be issued before the expiration of 30 days from (1) the
publication of a notice in the Federal Register of the intention to
issue such order and the grounds upon which such order is to be issued,
and (2) the date that notice of a proposed temporary scheduling order
is transmitted to the Assistant Secretary of HHS. 21 U.S.C. 811(h)(1).
Inasmuch as section 201(h) of the CSA directs that temporary
scheduling actions be issued by order and sets forth the procedures by
which such orders are to be issued, the DEA believes that the notice
and comment requirements of section 553 of the Administrative Procedure
Act (APA), 5 U.S.C. 553, do not apply to this temporary scheduling
action. In the alternative, even assuming that this action might be
subject to section 553 of the APA, the Deputy Administrator finds that
there is good cause to forgo the notice and comment requirements of
section 553, as any further delays in the process for issuance of
temporary scheduling orders would be impracticable and contrary to the
public interest in view of the manifest urgency to avoid an imminent
hazard to the public safety.
Further, the DEA believes that this temporary scheduling action
final order is not a ``rule'' as defined by 5 U.S.C. 601(2), and,
accordingly, is not subject to the requirements of the Regulatory
Flexibility Act (RFA). The requirements for the preparation of an
initial regulatory flexibility analysis in 5 U.S.C. 603(a) are not
applicable where, as here, the DEA is not required by section 553 of
the APA or any other law to publish a general notice of proposed
rulemaking. Additionally, this action is not a significant regulatory
action as defined by Executive Order 12866 (Regulatory Planning and
Review), section 3(f), and, accordingly, this action has not been
reviewed by the Office of Management and Budget (OMB).
This action will not have substantial direct effects on the States,
on the relationship between the national government and the States, or
on the distribution of power and responsibilities among the various
levels of government. Therefore, in accordance with Executive Order
13132 (Federalism) it is determined that this action does not have
sufficient federalism implications to warrant the preparation of a
Federalism Assessment.
Pursuant to section 808(2) of the Congressional Review Act (CRA),
``any rule for which an agency for good cause finds[hellip]that notice
and public procedure thereon are impracticable, unnecessary, or
contrary to the public interest, shall take effect at such time as the
Federal agency promulgating the rule determines.'' It is in the public
interest to schedule these substances immediately because they pose a
public health risk. This temporary scheduling action is taken pursuant
to section 811(h), which is specifically designed to enable the DEA to
act in an expeditious manner to avoid an imminent hazard to the public
safety from new or designer drugs or abuse of those drugs. Section
811(h) exempts the temporary scheduling order from standard notice and
comment rulemaking procedures to ensure that the process moves swiftly.
For the same reasons that underlie section 811(h), that is, the DEA's
need to move quickly to place these substances into schedule I because
they pose a threat to public health, it would be contrary to the public
interest to delay implementation of the temporary scheduling order.
Therefore, in accordance with section 808(2) of the CRA, this order
shall take effect immediately upon its publication.
List of Subjects in 21 CFR Part 1308
Administrative practice and procedure, Drug traffic control,
Reporting and recordkeeping requirements.
Under the authority vested in the Attorney General by section
201(h) of the CSA, 21 U.S.C. 811(h), and delegated to the Deputy
Administrator of the DEA by Department of Justice regulations, 28 CFR
0.100, Appendix to Subpart R, the Deputy Administrator hereby intends
to order that 21 CFR part 1308 be amended as follows:
PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES
0
1. The authority citation for part 1308 continues to read as follows:
Authority: 21 U.S.C. 811, 812, 871(b), unless otherwise noted.
0
2. Section 1308.11 is amended by adding paragraphs (h)(12), (13), and
(14) to read as follows:
Sec. 1308.11 Schedule I.
* * * * *
(h) * * *
(12) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine,
its optical, positional, and geometric isomers, salts and salts of
isomers--7538 (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5)
(13) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)ethanamine, its optical, positional, and geometric
isomers, salts and salts of isomers--7537 (Other names: 25C-NBOMe; 2C-
C-NBOMe; 25C; Cimbi-82)
(14) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine,
its optical, positional, and geometric isomers, salts and salts of
isomers--7536
(Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)
Dated: November 7, 2013.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2013-27315 Filed 11-14-13; 8:45 am]
BILLING CODE 4410-09-P